Amorfix offers unique antibodies and reagents for sale

TSX: AMF

TORONTO , Oct. 22 /CNW/ - Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix's proprietary antibodies and reagents.

"Amorfix has developed the world's most sensitive diagnostic assays for variant Creutzfeldt-Jakob Disease (vCJD) and for aggregated Abeta, the hallmark of Alzheimer's Disease (AD). Consequently, we have received numerous inquiries from investigators involved in protein misfolding studies for our reagents," said Dr. George Adams , CEO of Amorfix. "By making these reagents accessible, we offer the research community the opportunity to find new applications for these high-quality antibodies that have demonstrated their superior sensitivity and specificity in our detection assays."

Amorfix products offered for research purposes only through Cedarlane include:

    
    -   Antibody to a Disease Specific Epitope (DSE) on the misfolded
        superoxide dismutase-1 (SOD1) protein, implicated in Amyotrophic
        Lateral Sclerosis (ALS) - Cedarlane catalogue number CLPN40023.

    -   Antibodies for the detection of aggregated beta-amyloids, targeting
        the C-terminus and N-terminus regions - Cedarlane catalogue numbers
        CLPN40018, CLPN40027 and CLPN40028. These antibodies are components
        of the Amorfix A4 test used for early detection of aggregated Abeta
        in transgenic mouse models of AD.

    -   The highest purity 3F4 prion detection antibody available in the
        market - Cedarlane catalogue number CLPN40020.

    -   Peroxynitrite solution for nitrating and oxidizing amino acid side
        chains - Cedarlane catalogue number CLPN40015. Peroxynitrite is
        currently used in the Epitope Protection assay for modifying epitopes
        on the prion protein.
    

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, variant Creutzfeldt-Jakob Disease (vCJD) and Cancer. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes (DSE) on the molecular surface of misfolded proteins. ProMIS(TM) is an "in silico" rational selection approach that can be applied to any protein where the normal folding structure is at least partially known. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer's disease and Cancer. The Company's diagnostic programs include a blood screening test for diagnosis of vCJD and an ultrasensitive method for the detection of aggregated ss-Amyloid in brain tissue of animal models of Alzheimer's disease, months prior to plaque formation.

About Cedarlane

Cedarlane Laboratories Limited is a leading supplier of antibodies and other research reagents in Canada and world-wide through an established network of international distributors. Cedarlane has a Canadian customer base of over 25,000 life science researchers, clinicians and technologists, and is certified under ISO 9001 and ISO 13485.

Access Amorfix products in Cedarlane's catalogue with this link: http://www.cedarlanelabs.com/Canada/search.asp?sb=0&q=clpn&s=

Forward-Looking Information

This press release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

%SEDAR: 00022789E

For further information: Dr. George Adams, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: [phone], Fax: [phone], [email protected]; James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: [phone], Fax: [phone], [email protected]